A comprehensive study of clinical and molecular features in patients with metastatic colorectal cancer with and without liver mets. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...
Tumor-suppressive miRNAs inhibit oncogenic pathways, preventing cancer progression, while oncogenic miRNAs promote tumor growth by targeting tumor suppressor genes. miRNA, microRNA. Lung cancer (LC) ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...
FAYETTEVILLE, GA, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Understanding why cancer cells rely on specific ...
Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 Representative KRAS-directed ...
As reviewed above, much has been learned over the past 20 years regarding the pathways that KRAS engages and requires during lung tumorigenesis, and specific inhibitors of these downstream signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results